Stuck for less

The proper response to the upjacking of the price of the EpiPen, courtesy of the FDA:

US regulators have approved new competition for EpiPen, the emergency allergy medicine that made Mylan a poster child for pharmaceutical company greed.

The Food and Drug Administration on Thursday approved Adamis Pharmaceuticals Corp.’s product, which should go on sale later this year.

Symjepi is a syringe prefilled with the hormone epinephrine, which helps stop life-threatening allergic reactions from insect stings and bites, foods such as nuts and eggs, or certain medications.

San Diego-based Adamis says its product is easier to use than Mylan’s EpiPen, a spring-loaded syringe filled with a set dose that comes with a training device.

Symjepi also is smaller than EpiPen, so it’s easier to fit in a pocket or purse.

Yes, but is it kinder to your wallet?

Adamis said it is still lining up a distributor so it hasn’t set the exact price for its product, which will be sold in pairs like EpiPen.

Adamis spokesman Mark Flather said Symjepi is intended to be a “low-cost alternative” to EpiPen and similar products, and the company is aiming to sell it for less than generic EpiPens.

We’ll have to keep an eye out for it.

(Via Fark.)





1 comment

  1. Holly H »

    20 June 2017 · 12:32 pm

    I applaud the competition. However, Big Pharma is kind of like Big Internet. There isn’t really any competition to speak of. And, like the internet, this is a critical need for all of us, so it should be regulated.

RSS feed for comments on this post